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Lewy bodies, mainly composed of α-synuclein (αS), are pathological hallmarks of 
Parkinson’s disease (PD) and dementia with Lewy bodies (DLB).  Epidemiological 
studies showed that green tea consumption or habitual intake of phenolic compounds 
reduced PD risk.  We previously reported that phenolic compounds inhibited αS 
fibrillation and destabilized preformed αS fibrils.  Cumulative evidences suggest that 
low-order αS oligomers are neurotoxic and critical species in the pathogenesis of 
α-synucleinopathies.  To develop disease modifying therapies for α-synucleinopathies, 
we examined effects of phenolic compounds (myricetin (Myr), curcumin, rosmarinic 
acid (RA), nordihydroguaiaretic acid, and ferulic acid) on αS oligomerization.  Using 
the methods of photo induced cross-linking of unmodified proteins, circular dichroism 
spectroscopy, the electron microscope, and the atomic force microscope, we showed 
that Myr and RA inhibited αS oligomerization and secondary structure conversion.  
The nuclear magnetic resonance analysis revealed that Myr directly bound to the 
N-terminal region of αS, on the other hand, direct binding of RA to monomeric αS was 
not detected.  Electrophysiological assays for long-term potentiation in mouse 
hippocampal slices revealed that Myr and RA ameliorated αS synaptic toxicity by 
inhibition of αS oligomerization.  These results suggest that Myr and RA prevent αS 





Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and multiple system 
atrophy (MSA) belong to the category of α-synucleinopathies.  PD is characterized by 
the loss of nigrostriatal dopaminergic neurons associated with motor impairment, and 
the main symptoms of PD are muscle rigidity, resting tremor, bradykinesia, and postural 
instability (Jankovic 2008).  In PD, neurodegenerative lesions with Lewy bodies (LBs) 
are distributed mainly in the dopaminergic neurons of the substantia nigra, and also in 
other brain stem and limbic regions (Braak et al. 2004).  DLB is a disorder of 
progressive dementia characterized by fluctuation in mental decline, visual hallucination, 
parkinsonism, and widespread distribution of LBs in the brain (McKeith et al. 2005).  
LBs are the accumulation of intracellular inclusions of the insoluble protein, which are 
mainly composed of α-synuclein (αS), and are pathological hallmarks of diseases 
known as PD and DLB (McKeith et al. 2005; Spillantini et al. 1998). 
αS is a neuronal presynaptic protein, involved in vesicular trafficking, 
neurotransmitter release, and regulation of neurotransmission (Clayton and George 
1999; Fujiwara et al. 2002).  The monomeric αS is natively unfolded soluble protein 
without well-defined secondary or tertiary structures (Weinreb et al. 1996), but it 
transforms into cross-β-sheet rich amyloid by self-assembly at physiological conditions 
via partially folded intermediates and soluble oligomers (Uversky et al. 2001).  While 
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the intimate origin for the αS toxicity is yet to be unclear, accumulated evidences 
suggest that oligomeric forms of αS, rather than the larger intracellular inclusions, might 
be more bioactive and, possibly, cytotoxic, causing not only neuronal dysfunction but 
cell death (Martin et al. 2012; Winner et al. 2011).   
Epidemiological studies showed an inverse relationship between green tea 
consumption and the risk of developing PD (Ascherio et al. 2001; Chan et al. 1998).  
The major polyphenols present in green tea are catechins, especially epigallo catechin 
3-gallate (EGCG), and green tea contains more myricetin (Myr) compared with black 
tea (Bosetti et al. 2005).  Recently, a prospective study showed habitual intake of some 
polyphenols may reduce PD risk, and the association was more pronounced in men than 
women (Gao et al. 2012).   
Evidences of in vitro and in vivo studies have indicated the protective effects of 
polyphenols, such as EGCG in green tea, curcuminoids in curry, baicalein extracted 
from the root of Scutellaria baicalensis, a traditional Chinese herb, or extracts from 
grape and blueberry, against neuronal damage in PD (Chao et al. 2012; Masuda et al. 
2006).  Levites et al. reported the neuroprotective activity of EGCG on 
1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP)-induced parkinsonism in animal 
models (Levites et al. 2001).  It is suggested that the neuroprotective effects of EGCG 
are mediated by iron-chelating activities and free-radical-scavenging activities 
possessed by the cathecol group (Weinreb et al. 2009).  Polyphenols also have 
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protective effects against αS toxicity (Liu et al. 2011; Jiang et al. 2013).  In PD cell 
model experiments, Curcumin (Cur) reduced αS induced cytotoxicity by reduction of 
intracellular reactive oxygen species, mitochondrial depolarization, cytochrome c 
release, and caspase-9 and caspase-3 activation (Liu et al. 2011), or downregulation of 
mTOR/p70S6K signaling and the recovery of macroautophagy (Jiang et al. 2013). 
We showed that phenolic compounds such as the wine-related polyphenol Myr, a 
major component of curry spice turmeric Cur, rosmarinic acid (RA), 
nordihydroguaiaretic acid (NDGA), and ferulic acid (FA) inhibited the formation of αS 
fibrils (fαS), as well as destabilized preformed fibrils (Ono and Yamada 2006).  
Similarly, it was reported that baicalein (Zhu et al. 2004) and EGCG (Bieschke et al. 
2010; Ehrnhoefer et al. 2008) also inhibited fαS formation and destabilized preformed 
fαS.   
Given this background, we examined the ability of five phenolic compounds, Myr, 
FA, NDGA, Cur, and RA (Fig.1), to interact with αS and to inhibit the oligomerization 
of αS using well-established biophysical techniques.  We assessed the oligomerization 
of αS with the methods of photo induced cross-linking of unmodified proteins (PICUP), 
sodium dodecyl sulfate-polyaclylamidegel electrophoresis (SDS-PAGE), circular 
dichroism spectroscopy (CD), electron microscope (EM), atomic force microscope 
(AFM), and nuclear magnetic resonance (NMR) (Bitan and Teplow 2004; Ono et al. 
2008; Ono and Yamada 2011).  We also evaluated the seeding effect of oligomeric αS 
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using thioflavin S (ThS) assay (LeVine 1993; Naiki and Nakakuki 1996; Ono et al. 
2013).  Finally, we examined whether the phenolic compounds reduced αS 
oligomers-induced synaptic dysfunction with electrophysiological assays for long-term 
potentiation (LTP). 
 
Materials and methods 
Chemicals and reagents 
Chemicals were obtained from Sigma-Aldrich (St. Louis, MO, USA) and were of the 
highest purity available.  Water was produced using a Milli-Q system (Nihon Millipore 
K.K., Tokyo, Japan). 
 
Proteins and phenolic compounds 
αS peptides were obtained from r-peptide (Osaka, Japan), and were >95% purity.  
Purified peptides were stored as lyophilizates at -20°C.  To prepare peptides for study, 
αS peptide lyophilizates were dissolved at a nominal concentration of 50 µM in 20 mM 
Tris HCl buffer, pH 7.4.  The peptide solution was centrifuged for 30 min at 16,000 ×g 
at 4°C.  A stock solution of glutathione S-transferase (GST; ~26 kDa) (Sigma-Aldrich) 
was prepared by dissolving the lyophilizate to a concentration of 250 µM in 60 mM 
NaOH.  Prior to use, aliquots were diluted 10-fold into 20 mM Tris-HCl, pH 7.4.  We 
examined 5-phenolic compounds such as Myr, FA, NDGA, Cur, and RA.  They were 
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dissolved in ethanol to a final concentration of 2.5 mM and then diluted with 20 mM 
Tris HCl buffer, pH7.4, to produce concentrations 5, 10, 25, 50, 100, and 500 µM for 
CD, PICUP, and AFM as described previously (Bitan and Teplow 2004; Ono et al. 
2012a). 
 
Circular dichroism spectroscopy 
CD spectra of αS compound mixtures were acquired immediately after sample 
preparation or following 1-5 days of incubation.  CD measurements were made by 
removing a 200-µL aliquot from the reaction mixture, adding the aliquot to a 1-mm path 
length CD cuvette (Hellma, Forest Hills, NY), and acquiring spectra in a J-805 
spectropolarimeter (JASCO, Tokyo, Japan).  The CD curettes were maintained on ice 
prior to introduction into the spectrometer.  Following temperature equilibration, 
spectra were recorded at 22°C from ~190-260 nm at 0.2 nm resolution with a scan rate 
of 100 nm/min.  Ten scans were acquired and averaged for each sample.  Raw data 
were manipulated by smoothing and subtraction of buffer spectra according to the 
manufacturer’s instructions. 
 
Chemical cross-linking and determination of oligomer frequency distributions 
Immediately after their preparation, samples were cross-linked using PICUP, as 
described (Ono et al. 2012b).  Briefly, to 18 µM of 50 µM protein solution were added 
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1 µL of 4 mM tris(2,2’-bipyridyl)dichlororuthenium(II) (Ru(bpy)) and 1 µL of 80 mM 
ammonium persulfate.  The final protein of αS : Ru(bpy) : ammonium persulfate molar 
ratios were 1 : 4 : 80.  The mixture was irradiated for 1 s with visible light, and then 
the reaction was quenched with 2 µL of 1 M DTT (Invitrogen) in ultrapure water.  
Determination of the frequency distribution of monomers and oligomers was 
accomplished using SDS-PAGE and silver staining as described (Ono et al. 2012b).  
Briefly, 8 µL of each cross linked sample was electrophoresed on a 10-20% gradient 
tricine gel and visualized by silver staining (Invitrogen).  Uncross-linked samples were 
used as controls in each experiment.  Densitometry was performed with a luminescent 
image analyzer (LAS 4000 mini, Fujifilm, Tokyo, Japan) and image analysis software 
(Multi gauge, version 3.2, Fujifilm).  The intensity of each band in a lane from the 
SDS gel was normalized to the sum of the intensities of all the bands in that lane 
according to the formula,   =  / =1   ×100 (%), where Ri is the normalized intensity of 
band I, and Ii is the intensity of each band i.  Ri varies from 0-100.  To calculate the 
oligomer ratio, the sum of oligomers intensities of αS with 2.5, 5, 25, 50, and 250 µM 
Myr, FA, NDGA , Cur, or RA, respectively, was divided by the sum of oligomer 
intensities without each compound.  The EC50 was defined as the concentration of 
phenolic compounds to inhibit α synuclein oligomerization to 50% of the control value.  
The EC50 was calculated by sigmoidal curve fitting, using GraphPad Prism software 





PICUP reagents and phenolic compounds were removed from cross-linked samples 
by size-exclusion chromatography (SEC) as described previously (Ono et al. 2012a; 
Volles et al. 2001).  To do so, we used the Superdex 200 10/300 GL column (GE 
healthcare, Tokyo, Japan).  At first, the column was washed twice with 0.5 M NaOH.  
Two hundred µL of cross-linked sample was then loaded.  The column was eluted with 
20 mM Tris HCl buffer at a flow rate of 0.5 mL/min.  The first 4 mL of elute was 
collected.  Fractions were lyophilized immediately after collection. 
 
Seeding activity of assemblies of αS 
For the seeding assay, uncross-linked αS or cross-linked αS with or without Myr and 
RA at a concentration of 25 µM in 20 mM Tris buffer, pH 7.4 were added as seeds to 
uncross-linked αS at a ratio of 10% (v/v).  The mixtures were incubated at 37°C for 
0-7 days.  ThS fluorescence were measured as mentioned below at 0, 1, 2, 6, 24. 48, 72, 
96, 120, 144, and 168 hrs.  Before the seeding assay, secondary structure of each αS 
assembly was checked, using CD studies. 
 
Thioflavin S binding 
Thioflavin binding assays were performed because fluorescence intensities do 
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correlate with αS fibril content (LeVine 1993; Naiki and Nakakuki 1996).  The 
reaction mixture contained 5 µM ThS (MP Biomedicals, Irvine, CA, USA) and 50 mM 
glycine-NaOH buffer, pH 8.5.  After brief vortexing, fluorescence was determined 
three times at intervals of 10 s using a Hitachi F-7500 fluorometer (Hitachi, Tokyo, 
Japan).  Excitation and emission wavelength of 440 and 521 nm were used for αS 
assay, respectively.  Fluorescence was determined by averaging three readings and 
subtracting the ThS blank readings.   
 
Electron microscope 
A 10-µL aliquot of each sample was spotted onto a glow-discharged, carbon-coated 
formvar grid (Okenshoji, Co, Ltd, Tokyo, Japan) and incubated for 20 minutes.  The 
droplet then was displaced with an equal volume of 2.5% (v/v) glutaraldehyde in water 
and incubated for an additional 5 minutes.  Finally, the peptide was stained with 8 µL 
of 1% (vol/vol) filtered (0.2 µm) uranyl acetate in water (Wako Pure Chemical 
Industries, Ltd, Osaka, Japan).  This solution was wicked off and then the grid was 
air-dried.  The samples were examined using a JEM-1210 transmission EM (JEOL 
Ltd., Tokyo, Japan). 
 
Atomic force microscope 
Peptide solutions were characterized using a Nanoscope IIIa controller (Veeco Digital 
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Instruments, Santa Barbara, CA, USA) with a multimode scanning probe microscope 
equipped with a JV (J-type vertical) scanner.  All measurements were carried out in the 
tapping mode under ambient conditions using single-beam silicon cantilever probes.  
A 10-µL aliquot of each sample was spotted onto freshly cleaved mica (Ted Pella, Inc., 
Redding, CA, USA), incubated at room temperature for 5 minutes, rinsed with water, 
and then blown dry with air.  At least 4 regions of the mica surface were examined to 
confirm the homogeneity of the structures throughout the sample.  Mean particle 
heights were analyzed by averaging the measured values of 8 individual cross-sectional 
line scans from each image only when the particle structure was confirmed. 
 
Electrophysiology 
The field excitatory postsynaptic potentials (fEPSPs) were recorded from the CA1 
region of acute hippocampal slices derived from C57BL/6 mice (male, 4-5 weeks of 
age).  The procedures for slice preparation and electrophysiological recording were 
described previously (Takamura et al. 2014).  Briefly, 300-µm thick transverse 
hippocampal slices were placed in a physiological chamber perfused with artificial 
cerebrospinal fluid (125 mM NaCl, 3.5 mM KCl, 1.25 mM NaH2PO4, 25 mM NaHCO3, 
2.0 mM MgSO4, 2.0 mM CaCl2, and 20 mM glucose and aerated with a mixture of 95% 
O2 and 5% CO2) at a rate of 1 mL/min at 30°C.  Shaffer collaterals/commissural 
bundle in the CA3 hippocampal subfield were stimulated using a bipolar stainless steel 
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wire electrode at 20-s intervals throughout the experiment.  The fEPSPs were recorded 
from the stratum radiatum in the CA1 hippocampal subfield using a sharp glass 
electrode (2-6 Mohms, filled with 2 M NaCl).  After fEPSP baseline became stabilized, 
slice was incubated with circulation of 10 ml αS sample (1 µM) for 90 min on the 
experimental chamber without electric stimulation.  fEPSP recording was restarted 
after incubation and confirmed baseline stability at least 20 min.  LTP was induced by 
two train of tetanic stimulation delivered at 100 Hz for 1 s.  The evoked potential was 
amplified (×1000), filtered (0.1-1000Hz), digitized (20 kHz), and stored in a computer 
for off-line analysis using the PowerLab system (AD Instruments, Colorado Springs, 
CO).  LTP values were presented as the percentage of average fEPSPs slope relative to 
the mean value of the base line before tetanic stimulation. 
 
NMR spectroscopy 
The synthetic DNA encoding human αS was inserted into pOPTH plasmid. 
Sequencing of the inserted DNA was performed on an ABI PRISM 3130 Genetic 
Analyzer (Applied Biosystems).  The αS protein with an N-terminal His-tag 
(MAHHHHHH) was expressed in E. coli BL21(DE3) harboring the pOPTH plasmid. 
The cells were grown in M9 minimal medium supplemented with 15NH4Cl and 
13C-glucose. Purification of αS was done with a Ni-NTA agarose resin (QIAGEN), 
followed by further purification by gel-filtration on a Superdex 75 16/60 column (GE 
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Healthcare Bio-Sciences).  Matrix-assisted laser desorption ionization time-of-flight 
mass (MALDI-TOF MS) analysis showed that His-tagged αS has no methionine at the 
N-terminus.  MALDI-TOF MS analysis was performed on a Bruker Daltonics 
Autoflex-T1 mass spectrometer. 
Stock solutions of Myr and RA (54 mM) were prepared by dissolution in 
dimethylsulfoxide. Aliquots of the phenolic solutions were mixed with a solution 
containing 41 µM 13C/15N-synuclein, 10 mM HEPES (pH 7.4), 50 mM NaCl, 90 µM 
NaN3, 90 µM 2,2-dimethyl-2-silapentane-5-sulfonate sodium salt and 10% D2O.  The 
polyphenol concentration was 0.41 mM so that the final αS : polyphenol concentration 
ratio was 1 : 10.  An NMR sample of the αS alone was also prepared in the same 
manner without polyphenol.  The NMR sample was incubated at 15°C for 6 days 
before NMR measurements.  All NMR spectra were obtained at 15°C with a Bruker 
Avance 800 MHz spectrometer equipped with a cryoprobe (Bruker BioSpin, 
Rheinstetten, Germany).  NMR data were processed with NMRPipe (Delaglio et al. 
1995) and analyzed with NMRView (Johnson. 2004).  The published backbone 
resonance assignments of αS (BMRB Entry 16300) were transferred to the data of 
His-tagged αS without polyphenol (Rao et al. 2009).  The transferred assignments 
were confirmed by analyzing CBCANH, CBCA(CO)NH, HNCO and HN(CA)CO 





NMR-based molecular modeling 
The model of αS was obtained with the use of CS-ROSETTA and the chemical shift 
assignment data (Rao et al. 2009; Shen et al. 2008; Shen et al. 2009).  CS-ROSETTA 
generated the ensemble of the disordered αS, and one of them was used to show the 
regions affected by the polyphenol-binding.  Figure depicting the αS model were 
prepared with the program PyMOL (DeLano Scientific, New York, USA). 
 
Statistical analysis 
Dunnett multiple comparisons were used to determine statistical significance between 
cross-linked αS group versus other groups in LTP analysis.  These tests were 
implemented within GraphPad Prism software (MDF, Tokyo, Japan).  Significance 




To determine whether the five phenolic compounds blocked formation of low n-order 
αS oligomers, we used PICUP, a photochemical cross-linking method that is rapid, 
efficient, requires no structural modification of αS, and accurately reveals the 
oligomerization state of αS (Bitan and Teplow 2004).  Following cross-linking as 
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reported previously (Ono et al. 2012b), αS existed predominately as a mixture of 
monomers and oligomers of order 2-4, and higher order oligomers appear as smear 
bands (Fig. 2A).  When 25 µM Myr was mixed with αS at a peptide : compound ratio 
of 1 : 1, oligomerization was blocked, bands of tetramer and higher order oligomers 
disappeared, and intensity of trimer band was decreased (Fig. 2A).  When 250 µL of 
Myr was mixed with αS at a peptide : compound ratio of 1 : 10, oligomerization was 
blocked almost completely (Fig. 2A).  When 25 (1 : 1) or 250 µM (1 : 10) RA was 
mixed with αS at the same ratios as used above, comparable effects were observed on 
αS oligomerization (Fig. 2A). 
With αS : FA at a 1 : 1 ratio, intensities of bands of tetramer and higher order 
oligomers were decreased (Fig. 2A).  At a higher concentration of FA (αS : FA, 1 : 10), 
oligomerization was blocked almost completely.  With αS : NDGA at a 1 : 1 ratio and 
1 : 10 ratio, similar effects was observed on αS oligomerization (Fig. 2A).  With αS : 
Cur at a 1 : 1 ratio, no inhibition of αS oligomerization was observed.  With αS : Cur at 
a 1 : 10 ratio, tetramer band was disappeared, and intensity of trimer band was 
decreased. 
The results indicated that Myr and RA had the stronger inhibitory effects on αS 
oligomerization, compared to FA, NDGA, and Cur.  We confirmed dose dependence 
of inhibitions by Myr and RA (Fig. 2, C and D).  The EC50 of Myr and RA for the αS 
oligomerization were 23.9 and 22.7 µM, respectively.   
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A potential problem relates to the possibility that the inhibition of αS oligomerization 
could have resulted from an alternative compound, which may form from a possible 
side reaction of the inhibitor and the PICUP sensitizer.  To evaluate this possibility, 
cross-linking reactions also were performed on GST, a positive control for the 
cross-linking chemistry (Fancy and Kodadek 1999).  Uncross linked GST exhibited an 
intense monomer band and a relatively faint dimer band (Fig. 2B).  Cross-linking 
produced an intense dimer band, which was expected because GST exists normally as a 
homodimer, as well as higher-order cross-linked species.  No alterations in GST 
cross-linking were observed in the presence of Myr, FA, NDGA, Cur, or RA at either of 
the two protein : compound ratios tested, 1 : 1, 1 : 10.  Thus, the significant inhibition 
of αS oligomerization is from a direct interaction with the phenolic compounds. 
 
Size-exclusion chromatography 
The waves of SEC were shown in Figure S1A.  Reconstitution of the lyophilizates 
to a nominal concentration of 25 µM in 20 mM Tris HCl buffer, pH 7.4, followed by 
SDS-PAGE analysis, showed that removal of reagents and phenolic compounds, 
lyophilization and reconstitution did not alter the oligomer composition of any of the 
peptide populations under study (Figure S1B).   
 
αS assembly morphology 
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We used AFM and EM to determine the morphology of the small assemblies present 
following PICUP of αS with or without phenolic compounds.  The height of 
uncross-linked αS was 0.53 ± 0.05 nm (Fig. 3 and Table 1) from AFM analysis.  
Following PICUP, the height of αS oligomers became 1.60 ± 0.24 nm.  These 
morphologies are consistent with our previous findings (Ono et al. 2011; Ono et al. 
2012b).  When αS was cross-linked with Myr at a compound : peptide ratio of 1 : 2, 
the height of treated αS decreased to 0.58 ± 0.06 nm.  When αS was cross-linked with 
RA at a compound : peptide ratio of 1 : 2, the height of treated αS was decreased to 0.57 
± 0.06 nm (Fig. 3 and Table 1).  Similarly, when αS was cross-linked with NDGA, FA, 
or Cur at a compound : peptide ratio of 1 : 2, the height of treated αS decreased to 0.54 
± 0.06 nm, 0.57 ± 0.07 nm, or 0.60 ± 0.07 nm, respectively. 
Similar data were obtained from EM analysis.  The diameter of uncross-linked αS 
was 2.32 ± 0.17 nm.  Following PICUP, the diameter of αS oligomers became 11.94 ± 
1.51 nm.  These morphologies are also consistent with our previous findings (Ono et al. 
2012b).  When αS was cross-linked with Myr, NDGA, FA, Cur, or RA at a 
compound : peptide ratio of 1 : 2, the diameters of treated αS decreased to 2.80 ± 0.34 
nm, 2.70 ± 0.27 nm, 2.99 ± 0.38 nm, 3.15 ± 0.38 nm, or 2.67 ± 0.35 nm, respectively 
(Table 1). 
 
αS secondary structure dynamics 
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The above oligomerization studies revealed effects of the phenolic compounds at the 
initial stages of peptide self-association.  To examine whether the phenolic compounds 
altered the secondary structure of the αS, we undertook CD studies (Fig. 4).  αS, 
incubated alone, produced initial spectra characteristic of statistical coils (Fig. 4A).  
The major feature of these spectra was a large magnitude minimum centered at ~198 nm.  
αS displayed substantial secondary structure changes between days 2-3 that were 
consistent with the previous study (Ono et al. 2012b).  When αS were incubated with 
Myr and RA at a compound : peptide ratio of 1 : 2, no such transitions were observed 
(Fig. 4, B and C). 
 
Secondary structures of αS assembly 
We measured secondary structure of seeds, such as uncross-linked αS, cross-linked 
αS with or without Myr or RA, using CD studies.  The seed of cross-linked αS without 
phenolic compounds produced spectrum characteristic of β-sheet, on the other hand, the 
seeds of uncross-linked αS and cross-linked αS with Myr or RA produced spectrum 
characteristic of statistical coils (Figure S2A).  
  
Seeding activities of αS assemblies 
αS fibril assembly proceeds along a nucleation-dependent polymerization process 
(Wood et al. 1999).  To monitor the abilities of cross-linked αS with or without 
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phenolic compounds to exert fibril formation as seeds, we measured the time 
dependence of ThS fluorescence in seeded fibril formation experiments (Figure S2B).  
Uncross-linked αS displayed a quasisigmoidal process curve characterized by an ~6 hr 
lag time, an ~96 hr period of increasing ThS binding, and a binding plateau occurring 
after ~120 hr (Figure S2B).  The unseeded reaction did not display initial fluorescence 
increase, within experimental error.  Adding 10% cross-linked αS oligomers 
eliminated the lag period and produced a quasihyperbolic increase in fluorescence that 
reached maximal levels at ~48 hr, suggesting that cross-linked αS oligomers functioned 
as seeds.  However, this seeding activity had disappeared in the cross-linked αS with 
Myr or RA (Figure S2B).  Maximal ThS levels for the αS oligomers seeded reaction 
was reached in 72 hr, whereas those of seeded with uncross-linked αS, and cross-linked 
αS with Myr or RA reached in 120 hr. 
 
Electrophysiology 
To obtain an index of cross-linked αS-induced functional alteration of synaptic 
transmission, we analyzed LTP in the CA1 region of mouse hippocampal slices.  
Synaptic current strength was estimated from fEPSP slope (Fig. 5).  The vehicle group 
indicated LTP by tetanus stimulation (166 ± 7.6%).  Uncross-linked αS did not affect 
LTP (177 ± 15.5%).  Cross-linked αS completely inhibited induction of LTP (87 ± 
19.4%).  In contrast, cross-linked αS treated with Myr and RA induced LTP 
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comparable with that in the vehicle (150 ± 15.6% and 155 ± 18.1%, respectively).  Fig. 
5 shows differences in LTP induction among the five treatment groups.  There was a 
significant group effect on %fEPSP slope in the cross-linked αS group was significantly 
lower than those in the other four groups, indicating that cross-linked αS induced LTP 
suppression, but cross-linked αS treated with Myr and RA did not. 
 
NMR studies 
In order to study the interaction between the phenolic compounds and αS, we utilized 
NMR spectroscopy, a widely accepted method to obtain atomic level aspects of protein 
structure and ligand binding.  Fig. 6 shows the overlaid 1H-15N HSQC spectra of the 
αS alone and the αS containing the phenolic compounds at 1 : 10 molar ratio (αS : 
polyphenol).  The 1H-15N HSQC spectra of αS are typical of an unstructured protein 
with limited resonance dispersion in the proton dimension (Wu et al. 2008). 
Myr causes the reduction in the signal intensities due to the broadening of NMR 
resonances (Fig. 6A). The broadening results from the interactions between Myr and αS.  
Severe broadening was observed only within the first nine residues of αS, indicating 
that the N-terminal region was involved in the Myr-binding (Fig. 6A).  On the other 
hand, neither chemical shift changes nor line broadening was observed upon RA 





We previously reported that several antioxidants including the phenolic compounds, 
Myr, FA, NDGA, Cur, and RA, had the inhibitory effects on αS fibrillization and αS 
fibril–destabilizing effect (Ono et al. 2003).  In this study, we revealed that all five 
phenolic compounds had dose-dependently inhibitory effects on αS oligomerization, 
using the PICUP studies.  Using EM and AFM analysis, the diameters and the heights 
of cross-linked αS treated with phenolic compounds were smaller than cross-linked αS 
oligomers.  The CD studies unraveled that Myr and RA stabilized αS populations 
comprising mostly random coil and inhibited statistical coils → β-sheet conversion.  In 
ThS assay, cross-linked αS treated with Myr and RA lost seeding activities.  Taken 
together, we revealed that the abilities of Myr and RA to inhibit αS oligomerization and 
secondary structure conversion.  To unravel chemical and neurophysiological basis for 
these effects, we performed LTP experiment and NMR analysis.  Myr and RA 
decreased synaptic toxicities induced by αS oligomers on LTP assay of hippocampal 
slices.  NMR showed the direct binding of Myr to the first nine residues of the 
N-terminal region of the monomeric αS protein, on the other hand, the direct binding of 
RA to the αS monomer was not detected. 
What is the mechanism underlying the inhibitory effects of the phenolic compounds 
on αS oligomerization?  The binding of Myr to the first nine residues of the 
N-terminus of αS in the NMR experiment might contribute to inhibition of αS 
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oligomerization.  The sequence of αS can be divided into three domains: the 
N-terminal domain, the central fragment, also known as NAC (non-amyloid β 
component) region, and the C-terminal region.  NAC region (residues 61-95) was 
reported to represent the critical determinant of the oligomerization and the fibrillation 
process of αS (Hejjaoui et al. 2012).  The C-terminal region (residues 96-140) is 
highly disordered and negatively charged, and it was shown that negatively charged side 
chains located in C-terminal region of αS acted to retard fibril formation by thioflavin T 
(ThT) binding assay (Izawa et al. 2012).  Similar to Myr, a small molecular tweezer, 
CLR01, was recently reported to bind selectively to Lys side chains at the N-terminal 
region of αS and prevent its aggregation by electron-capture dissociation 
mass-spectrometry and PICUP study (Acharya et al. 2014).  Using ThT fluorescence 
and EM, it is shown that in the presence of CLR01, αS did not form amyloid fibrils, and 
demonstrated that CLR01 inhibited αS-mediated toxicity in cell cultures and zebrafish 
embryos (Prabhudesai et al. 2012).  The data of fluorescence and mass-spectrometric 
analysis suggested that CLR01 kept αS monomeric by increasing its reconfiguration rate 
(Acharya et al. 2014; Prabhudesai et al. 2012).  It was shown that the polyphenol 
3,4-dihydroxyphenylacetic acid (DOPAC) bound to the N-terminal region of αS and 
inhibited fibrillation of αS binding non-covalently (Zhou et al. 2009).  By deleting 
residues 2-11 in the N-terminal, αS aggregation was delayed and cellular membrane 
permeabilization of αS monomer and oligomer could be abolished (Lorenzen et al. 
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2014a).  It was shown that the N-terminal deletions in αS dramatically reduced toxicity 
towards yeast (Vamvaca et al. 2009).  On the other hand, an NMR analysis revealed 
that EGCG noncovalently bound to C–terminal region of the monomeric αS (D119, 
S129, E130, and D135), and redirected αS into unstructured, off-pathway αS oligomers 
(Ehrnhoefer et al. 2008).  EGCG did not affect oligomer size distribution or secondary 
structure, and rather, immobilized the C-terminal region and moderately reduced the 
degree of binding of oligomers to membrane (Lorenzen et al. 2014b).  Based on the 
results of these studies (Acharya et al. 2014; Prabhudesai et al. 2012; Zhou et al. 2009; 
Lorenzen et al. 2014a; Vamvaca et al. 2009) and our NMR study, the binding region of 
αS with phenolic compounds might make equilibrium shift of αS aggregation capacities 
among the N-terminal, NAC, and the C-terminal region toward the suppression of 
aggregation.  Interestingly, the anti-oligomerization effects of phenolic compounds on 
αS are similar to those on Aβ in our previous study (Ono et al. 2012a).  In our previous 
NMR study with Aβ, Myr showed binding to monomeric Aβ at Arg-5, Ser-8, Gly-9, 
His-13, Lys-16, Asp-23, and Ile-31 (Ono et al. 2012a).  There were no common amino 
acid sequences in Myr binding sites between Aβ and αS.  Unlike the result of Myr, we 
found no direct binding of RA to monomeric αS in NMR study.  In contrast, a previous 
NMR study reported the interaction between αS and RA, indicating that residues 3-18 
and 38-51 of αS acted as noncovalent binding sites for RA (Rao et al. 2008).  The 
discrepancy between the previous study (Rao et al. 2008) and the present study might 
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be related to the lower concentration of αS used in the present study.  
The ability of Myr and RA to block formation of low-order αS oligomers in our study 
is valuable, because low-order αS oligomers were thought to be the proximate 
neurotoxins in α-synucleinopathies from the results of several in vitro and in vivo 
studies (Outeiro et al. 2008; Paleologou et al. 2009; Tsigelny et al. 2008).  
Visualization of αS oligomerization in living cells using bimolecular fluorescence 
complementation revealed that formation of oligomeric αS species was a central step 
toward cytotoxicity, which can be targeted through the activity of molecular chaperones, 
such as heat shock protein 70 (Outeiro et al. 2008).  Consistent with this result, 
toxicity was seen without heavily aggregated αS in the experiment of dopaminergic and 
non-dopaminergic neurons, and it has been suggested that soluble species mediate 
toxicity (Xu et al. 2002).  We took into consideration these cumulative evidences, and 
performed LTP assay of hippocampal slices to evaluate synaptic toxicities induced by 
αS oligomers.  LTP has been widely used as a neurophysiological model of 
activity-dependent synaptic plasticity, and are considered as important 
neurophysiological models of learning and memory (Martin et al. 2000).  It has been 
reported that human Aβ oligomers inhibit hippocampal LTP in vitro and in vivo in rats 
(Townsend et al. 2006).  However, knowledge about the effects of αS oligomers on 
synaptic plasticity is currently limited.  It was reported that the exposure to αS 
oligomers impaired LTP through NMDA receptor activation, triggering enhanced 
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contribution of calcium-permeable AMPA receptors in rat hippocampus slices 
(Diógenes et al. 2012).  The application of extracellular αS oligomers was reported to 
induce LTP suppression in hippocampal neurons via a calcineurin-dependent 
mechanism (Martin et al. 2012).  Our work was consistent with previous studies 
(Martin et al. 2012; Diógenes et al. 2012), where αS oligomers, not monomers, 
suppressed LTP in the hippocampal CA1 subfield, suggesting that memory formation is 
disturbed by αS oligomers.  In contrast, cross-linked αS treated with Myr or RA partly 
cured LTP suppression.  This result suggests that Myr and RA have preventive effects 
on αS oligomer-induced synaptic dysfunction by interfering with αS oligomerization.  
In recent studies, Cur showed effectiveness on motor activity, lifespan, oxidative stress, 
and apoptosis in the transgenic Drosophila model of Parkinson’s disease (Siddique et al. 
2013; Siddique et al. 2014).  In vivo experiments with animal models of 
α-synucleinopathies should be conducted to elucidate the effectiveness of phenolic 
compounds on α-synucleinopathies. 
To develop the therapies for α-synucleinopathies by phenolic compounds, we need to 
overcome several issues.  The first issue is low bioavailability of phenolic compounds.  
Cur displayed low oral bioavailability, poor water-solubility, short biological half-life, 
and lower permeability through the brain blood barrier (BBB) (Anand et al. 2007).  
According to the data of clinical trial of Cur, bioavailability of Cur was not high; the 
range for serum concentration was between 0.51 ± 0.11 µ  M at a dose of 4000   mg/day 
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and 1.77 ± 1.87 µ  M at a dose of 8000   mg/day (Cheng et al. 2001).  A dose escalation 
study showed the safety of Cur intake in healthy volunteers, thus they took oral Cur 
ranged from 500 to 12000  mg and serious adverse events were not reported (Lao et al. 
2006).  To our best knowledge, there have been no reports about the orally-ingested 
Cur concentrations in cerebrospinal fluid.  We have insufficient knowledge about 
bioavailability of Myr and RA, and we need to obtain further information about 
bioavailability of phenolic compounds.  The next issue is the possibility that phenolic 
compounds may affect physiological functions of αS at synapses.  Further experiments 
are necessary to elucidate whether extracellular phenolic compounds or intracellular 
phenolic compounds taken into the cell alter the synaptic functions.  Specific targeting 
of extracellular αS has an additional advantage as a therapeutic strategy, as this 
approach will not interfere with the normal function of intracellular αS.  Although the 
most of αS, a neuronal presynaptic protein, exists intracellularly, the secreted 
extracellular αS, particularly in oligomerized forms, was reported to play important 
roles in major pathological changes of α-synucleinopathies: deposition and spreading of 
aggregates, neuroinflammation, and neurodegeneration (Lee et al. 2014).  We 
speculate that anti-oligomerization effects of phenolic compounds, such as Myr and RA, 
might reduce the formation of extracellular αS oligomers as well as intracellular αS 
oligomers, resulting in favorable effects on α-synucleinopathies. 
In conclusion, our data established that the phenolic compounds inhibit 
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oligomerization and statistical coils → β-sheet conversion of αS through different αS 
binding, and reduce αS oligomer-induced synaptic toxicity.  Although the exact in vivo 
mechanisms underlying the benefits of polyphenols remain to be established, the 
present data, coupled with previously reported antioxidant and neuroprotective effects, 
suggest that phenolic compounds would be considerable candidates of disease 
modifying therapies for α-synucleinopathies. 
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Fig. 1. Chemical structures of Myr, FA, NDGA, Cur, and RA. 
 
Fig. 2. αS and GST oligomerizations.  PICUP, followed by SDS-PAGE and silver 
staining, was used to determine the effects of 25 and 250 μM Myr, FA, NDGA, Cur, or 
RA on oligomerization of αS (A) or GST (B).  Consequently, we showed concentration 
dependent inhibitory effects of αS oligomerization of Myr (C) or RA (D). +, with 
cross-linking; -, without cross-linking.  The gel is representative of each of three 
independent experiments. 
 
Fig. 3. αS assembly morphology.  AFM was performed on 25 μM uncross-linked (A) 
and cross-linked (B-G) αS without (B) or with 50 μM Myr (C), FA (D), NDGA (E), Cur 
(F), or RA (G).  EM was performed on 25 μM uncross-linked (H) and cross-linked 
(I-N) αS without (I) or with 50 μM Myr (J), FA (K), NDGA (L), Cur (M), or RA (N).  
Scale bars indicate 100 nm. 
 
Fig. 4. αS secondary structure dynamics.  CD was used to monitor peptide assembly.  
25 μM αS (A-C) were incubated at 37°C for 5 days in 20 mM Tris-HCl buffer, pH 7.4, 
in buffer alone (A) or in the presence of 50 μM Myr (B) or RA (C).  Spectra were 
acquired immediately at the start of the incubation period, day 0 (○), and after days 1 
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(●), 2 (□), 3 (■), 4 (△), and 5 (▲).  The spectra presented at each time are 
representative of those obtained during each of three independent experiments. 
 
Fig. 5. Effects of Myr or RA on cross-linked αS-induced alterations of LTP in the 
hippocampal slices.  (A) Synaptic toxicity.  Typical fEPSP waveforms of pre- (black 
lines) and post-tetanic (dashed red lines) stimulation in each test group.  Thirty 
waveforms were averaged.  (B) Time course of %fEPSPs slope.  Arrows indicate 
tetanus stimulation (100 Hz, 1 s, 2 train).  (C) Values are shown as the percentage of 
fEPSP slope relative to the baseline and presented as mean ± S.E.  Significant 
difference between cross-linked αS versus other experimental group, along with their 
associated p-values, where * signifies p <0.05 and ** signifies p <0.01 
 
Fig. 6. Analysis of interaction between αS and polyphenols.  (A, B) 1H-15N HSQC 
spectra of αS in the absence of (black contour) and in the presence of (red contour) 
polyphenols. (A) Myr and (B) RA. Residues with intensity ratios (Ibound/Ifree) < 0.15 are 
labeled. An unassigned resonance is indicated by asterisk. (C, D) Model representation 
of αS that show binding locations with polyphenols. The red-colored regions are the 






Table 1. Morphological analysis of αS assemblies 
Assembly Diametera Heightb 
Uncross-linked αS 2.32 ± 0.17 (30) 0.53 ± 0.05 (30) 
Cross-linked αS 11.94 ± 1.51 (30) 1.60 ± 0.24 (30) 
Cross-linked αS with Myr 2.80 ± 0.34 (30) 0.58 ± 0.06 (30) 
Cross-linked αS with NDGA 2.70 ± 0.27 (30) 0.54 ± 0.06 (30) 
Cross-linked αS with FA 2.99 ± 0.38 (30) 0.57 ± 0.07 (30) 
Cross-linked αS with Cur 3.15 ± 0.38 (30) 0.60 ± 0.07 (30) 
Cross-linked αS with RA 2.67 ± 0.35 (30) 0.57 ± 0.06 (30) 
aMean diameter ± SE, in nanometers, is listed for (n) αS assemblies visualized by EM. 





Figure S1. Size exclusion chromatography (SEC) of αS assemblies.  SEC was 
performed on 25 µM cross-linked αS without phenolic compound (A), or with 50 µM 
Myr (B) or RA (C) for removing reagents.  Fractions were lyophilized immediately 
after collection.  Lyophilization and reconstitution did not alter the oligomer 
composition of any of the peptide populations under study (D).  Lanes 1-2 showed 
pre-SEC state of uncross-linked and cross-linked αS.  Lanes 3, 5, and 7 showed 
pre-SEC state, and Lanes 4, 6, and 8 showed post-SEC state of cross-linked αS without 
or with Myr or RA, respectively. 
 
Figure S2. The secondary structures and seeding activities of αS assemblies.  CD 
was used to measure the secondary structure of 25 µM uncross-linked αS (○; UnXL), 
cross-linked αS without (●; XL), or with 50 µM Myr (□; XL+Myr) or RA (×; XL+RA) 
(A).  10% (v/v) uncross-linked (○; UnXL), or 25 µM cross-linked αS without (●; 10% 
XL) or with Myr (□; 10% XL+Myr) or RA (×; 10% XL+RA) was added to un 
cross-linked αS, which then was incubated for 24-168 hr at 37°C in 20 mM Tris buffer, 
pH 7.4.  Aliquots were assayed periodically using ThS.  Binding is expressed as mean 
fluorescence (in arbitrary fluorescence units [FU]) ± SE.  ThS fluorescence were 
measured at 0, 1, 2, 6, 24. 48, 72, 96, 120, 144, and 168 hrs.  Data was obtained in 
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